You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

AVAGARD Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Avagard, and when can generic versions of Avagard launch?

Avagard is a drug marketed by 3M and is included in one NDA.

The generic ingredient in AVAGARD is alcohol; chlorhexidine gluconate. There are forty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alcohol; chlorhexidine gluconate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for AVAGARD?
  • What are the global sales for AVAGARD?
  • What is Average Wholesale Price for AVAGARD?
Summary for AVAGARD
Drug patent expirations by year for AVAGARD
Recent Clinical Trials for AVAGARD

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Universidad Autonoma de Nuevo LeonN/A
3MPhase 4

See all AVAGARD clinical trials

Pharmacology for AVAGARD
Physiological EffectDecreased Cell Wall Integrity

US Patents and Regulatory Information for AVAGARD

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
3m AVAGARD alcohol; chlorhexidine gluconate SOLUTION;TOPICAL 021074-001 Jun 7, 2001 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for AVAGARD

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
3m AVAGARD alcohol; chlorhexidine gluconate SOLUTION;TOPICAL 021074-001 Jun 7, 2001 ⤷  Sign Up ⤷  Sign Up
3m AVAGARD alcohol; chlorhexidine gluconate SOLUTION;TOPICAL 021074-001 Jun 7, 2001 ⤷  Sign Up ⤷  Sign Up
3m AVAGARD alcohol; chlorhexidine gluconate SOLUTION;TOPICAL 021074-001 Jun 7, 2001 ⤷  Sign Up ⤷  Sign Up
3m AVAGARD alcohol; chlorhexidine gluconate SOLUTION;TOPICAL 021074-001 Jun 7, 2001 ⤷  Sign Up ⤷  Sign Up
3m AVAGARD alcohol; chlorhexidine gluconate SOLUTION;TOPICAL 021074-001 Jun 7, 2001 ⤷  Sign Up ⤷  Sign Up
3m AVAGARD alcohol; chlorhexidine gluconate SOLUTION;TOPICAL 021074-001 Jun 7, 2001 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for AVAGARD

See the table below for patents covering AVAGARD around the world.

Country Patent Number Title Estimated Expiration
Germany 69723836 ⤷  Sign Up
Canada 2522124 DISTRIBUTEUR POUR LIQUIDES ANTIMICROBIENS (DISPENSER FOR ANTIMICROBIAL LIQUIDS) ⤷  Sign Up
Germany 69723834 ⤷  Sign Up
Austria 245936 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 9748321 ⤷  Sign Up
Canada 2224702 COMPOSITIONS HYDRO-ALCOOLIQUES STABLES (STABLE HYDROALCOHOLIC COMPOSITIONS) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.